Costly Brain-Cancer Drug No Longer Covered by Medicare
lomustine - List of nationally authorised medicinal products
Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, announced its randomized, controlled phase 2/3 clinical trial, called Toca 5, is now enrolling patients in South Korea. The trial is ongoing in the United States, Canada and Israel. The study compares a cancer-selective virus, Toca 511 (vocimagene amiretrorepvec), in combination with Toca FC (extended-release 5-fluorocytosine), to standard of care in patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection.
NextSource Biotechnology, LLC announced today that Gleostine® (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration (FDA) and is now commercially available in the United States. Gleostine® is approved for use as a single agent treatment or in combination with other approved chemotherapeutic agents. Gleostine® is indicated to treat brain tumors—both primary and metastatic, as well as Hodgkin's disease.